26 Leukemia Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Leukemia Studies in Tucson

NCT03959085Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial al...

Tucson, AZPHASE35,951 participantsChildren's Oncology Group

View Study Details

NCT04293562Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia...

Tucson, AZPHASE31,400 participantsChildren's Oncology Group

View Study Details

NCT04267848Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

Tucson, AZPHASE31,210 participantsNational Cancer Institute (NCI)

View Study Details

NCT06692738Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squam...

Tucson, AZPHASE31,160 participantsAstraZeneca

View Study Details

NCT04726241Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from pati...

Tucson, AZPHASE1960 participantsPedAL BCU, LLC

View Study Details

NCT06095583Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination w...

Tucson, AZPHASE3756 participantsShanghai Junshi Bioscience Co., Ltd.

View Study Details

NCT06623422Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want ...

Tucson, AZPHASE3680 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04613596Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and ...

Tucson, AZPHASE2626 participantsMirati Therapeutics Inc.

View Study Details

NCT06712355Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherap...

Tucson, AZPHASE3621 participantsBioNTech SE

View Study Details

NCT06852222Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukem...

Tucson, AZPHASE3600 participantsJanssen Research & Development, LLC

View Study Details

NCT07063745Recruiting

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...

Tucson, AZPHASE2590 participantsBristol-Myers Squibb

View Study Details

NCT05865301Recruiting

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozog...

Tucson, AZ500 participantsStanford University

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Tucson, AZPHASE3474 participantsNRG Oncology

View Study Details

NCT04546399Recruiting

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come ...

Tucson, AZPHASE2461 participantsNational Cancer Institute (NCI)

View Study Details

NCT06616584Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cel...

Tucson, AZPHASE2378 participantsSWOG Cancer Research Network

View Study Details

NCT05554406Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...

Tucson, AZPHASE2335 participantsNational Cancer Institute (NCI)

View Study Details

NCT04269902Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic ...

Tucson, AZPHASE3247 participantsNational Cancer Institute (NCI)

View Study Details

NCT06124157Recruiting

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-cl...

Tucson, AZPHASE2222 participantsNational Cancer Institute (NCI)

View Study Details

NCT06643221Recruiting

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a heal...

Tucson, AZEARLY_PHASE1200 participantsUniversity of Arizona

View Study Details

NCT06428019Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutini...

Tucson, AZPHASE3170 participantsAbbVie

View Study Details

NCT05554393Recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patien...

Tucson, AZPHASE2153 participantsNational Cancer Institute (NCI)

View Study Details

NCT07218341Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to thos...

Tucson, AZPHASE4150 participantsEli Lilly and Company

View Study Details

NCT06317649Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit...

Tucson, AZPHASE2147 participantsNational Cancer Institute (NCI)

View Study Details

NCT06672146Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed...

Tucson, AZPHASE293 participantsNational Cancer Institute (NCI)

View Study Details

NCT06069570Recruiting

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung ...

Tucson, AZPHASE148 participantsKiromic BioPharma Inc.

View Study Details

NCT07216209Recruiting

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-oper...

Tucson, AZNA48 participantsUniversity of Arizona

View Study Details

About Leukemia Clinical Trials in Tucson

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 26 leukemia clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 18,180 participants. Research is being sponsored by Children's Oncology Group, National Cancer Institute (NCI), AstraZeneca and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Tucson — FAQ

Are there leukemia clinical trials in Tucson?

Yes, there are 26 leukemia clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 26 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated October 12, 2026 from ClinicalTrials.gov